Subcutaneous fat necrosis of the newborn
| Subcutaneous fat necrosis of the newborn | |
|---|---|
| Synonyms | |
| Pronounce | N/A |
| Specialty | Dermatology, Pediatrics |
| Symptoms | Firm, red or purple nodules on the skin |
| Complications | Hypercalcemia, Thrombocytopenia |
| Onset | Within the first few weeks of life |
| Duration | Weeks to months |
| Types | N/A |
| Causes | Unknown, possibly related to birth asphyxia, hypothermia, or trauma |
| Risks | Perinatal stress, hypothermia, birth trauma |
| Diagnosis | Clinical examination, biopsy |
| Differential diagnosis | Sclerema neonatorum, Panniculitis |
| Prevention | N/A |
| Treatment | Supportive care, monitoring of calcium levels |
| Medication | |
| Prognosis | Generally good, but complications can occur |
| Frequency | Rare |
| Deaths | N/A |
Subcutaneous Fat Necrosis of the Newborn (SFNN) is a rare condition affecting the fat tissue (adipose tissue) located just beneath the skin. This condition is typically observed in newborns and is characterized by the formation of firm, reddish or purple nodules or plaques on the skin. These lesions are usually found on the back, buttocks, thighs, and arms of the affected infants. Despite its alarming appearance, SFNN is generally a self-limiting condition, meaning it often resolves on its own without the need for extensive treatment. However, it is crucial for healthcare providers to monitor affected infants closely for potential complications.
Causes and Risk Factors[edit]
The exact cause of Subcutaneous Fat Necrosis of the Newborn remains unclear, but it is believed to be associated with birth trauma, asphyxia, or hypothermia. Infants who experience significant stress during birth, such as those delivered with the assistance of forceps or vacuum extraction, or those who undergo cooling therapy for neonatal encephalopathy, are thought to be at higher risk. Maternal health conditions, including preeclampsia and gestational diabetes, may also contribute to the risk.
Symptoms[edit]
The primary symptoms of SFNN include the appearance of firm, nodular lesions on the skin. These nodules can vary in size and are typically reddish or purplish. The affected skin areas may appear swollen and can be tender to the touch. Although the condition primarily affects the subcutaneous fat layer, it does not usually cause systemic symptoms. However, in rare cases, SFNN can be associated with metabolic complications, such as hypercalcemia (high levels of calcium in the blood), which requires immediate medical attention.
Diagnosis[edit]
Diagnosis of Subcutaneous Fat Necrosis of the Newborn is primarily based on the clinical presentation and physical examination of the affected infant. In some cases, a biopsy of the lesion may be performed to confirm the diagnosis and rule out other conditions, such as infection or malignancy. Imaging studies, such as ultrasound, may also be used to assess the extent of the lesions.
Treatment[edit]
Treatment for SFNN is mainly supportive and focuses on managing symptoms and monitoring for potential complications. In most cases, the condition resolves spontaneously within weeks to months without any specific treatment. However, if an infant develops hypercalcemia, more aggressive management, including hydration and medications to lower the calcium level, may be necessary. Parents and caregivers should be educated about the condition and reassured about its benign nature and self-limiting course.
Prognosis[edit]
The prognosis for infants with Subcutaneous Fat Necrosis of the Newborn is generally excellent. The skin lesions typically resolve without scarring, although the resolution process can take several weeks to months. It is important to monitor affected infants for the development of hypercalcemia, which can occur weeks to months after the skin lesions appear. With appropriate monitoring and management of potential complications, infants with SFNN can expect a full recovery.
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
